AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trilaciclib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cyclin dependant kinase inhibitors | 5442 | 1374743-00-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.472 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.499 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 17.179 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 10 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 30.290 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 55.730 | % | High | 1 |
| herg | hERG pIC50 | 4.777 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.041 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 31.046 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 30.530 | % | High | 1 |
| kinase-safety-class | AAK1,ABL1,ABL2,ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK8,CDK9,CHEK1,CHEK2,CHUK,CLK1,CLK2,CLK4,CSF1R,CSK,CSNK1G2,CSNK2A2,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FGFR4,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K4,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK15,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK1,MKNK2,MST1R,MTOR,MYLK,NTRK1,NTRK2,NTRK3,NUAK1,PAK1,PAK2,PAK4,PAK5,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKACA,PRKCA,PRKCD,PRKCI,PRKCZ,PRKD1,PRKDC,PTK2,RET,RIPK3,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK10,STK16,STK17A,STK3,STK33,STK4,SYK,TBK1,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,UHMK1,ULK1,ULK2,YES1,ZAP70 | 180 | |||
| kinase-selectivity-class | AAK1,ABL2,ACVR2B,ALK,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK3,CDK4,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FYN,GAK,GSK3B,HIPK2,IGF1R,INSR,IRAK1,IRAK3,IRAK4,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK7,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK2,MST1R,NTRK1,NUAK1,PAK1,PAK4,PDGFRB,PDK1,PDK4,PIM3,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKCD,PTK2,RET,RIPK3,SIK2,SIK3,SRC,STK16,STK33,STK4,SYK,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1 | 104 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 16.331 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 26.669 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 21.990 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 24.210 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 36.370 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 14.521 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 61.800 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 18.050 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 15.066 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 12, 2021 | FDA | G1 THERAPEUTICS Inc |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AF12 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D047428 | Protein Kinase Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| FDA MoA | N0000187061 | Organic Cation Transporter 2 Inhibitors |
| FDA MoA | N0000191423 | Multidrug and Toxin Extrusion Transporter 1 Inhibitors |
| FDA MoA | N0000193921 | Cyclin-dependent Kinase 4 Inhibitors |
| FDA MoA | N0000193922 | Cyclin-dependent Kinase 6 Inhibitors |
| FDA MoA | N0000193932 | Multidrug and Toxin Extrusion Transporter 2 K Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
V03AF Detoxifying agents for antineoplastic treatment 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chemotherapy-induced myelosuppression | indication | 370569000 | |
| Extensive-stage small cell lung cancer | indication | 458321000124102 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10085992 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10966984 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10966984 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 11717523 | March 14, 2034 | A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 11717523 | March 14, 2034 | A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 9487530 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 9487530 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 12527798 | Dec. 5, 2037 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 11529352 | July 23, 2039 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 300MG BASE/VIAL | COSELA | PHARMACOSMOS | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | Feb. 12, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cyclin-dependent kinase 6 | Kinase | INHIBITOR | IC50 | 8.40 | DRUG LABEL | DRUG LABEL | |||
| Cyclin-dependent kinase 4 | Kinase | INHIBITOR | IC50 | 9 | DRUG LABEL | DRUG LABEL | |||
| Cyclin-dependent kinase 2 | Kinase | INHIBITOR | IC50 | 5.72 | DRUG LABEL | ||||
| Cyclin-dependent-like kinase 5 | Kinase | INHIBITOR | IC50 | 5.83 | DRUG LABEL | ||||
| Cyclin-dependent kinase 9 | Kinase | INHIBITOR | IC50 | 7.30 | DRUG LABEL | ||||
| Receptor-type tyrosine-protein kinase FLT3 | Kinase | INHIBITOR | Kd | 9.15 | DRUG LABEL | ||||
| NUAK family SNF1-like kinase 2 | Kinase | INHIBITOR | Kd | 9.15 | DRUG LABEL | ||||
| Serine/threonine-protein kinase Nek10 | Kinase | INHIBITOR | Kd | 9.57 | DRUG LABEL | ||||
| Cyclin-dependent kinase 7 | Kinase | INHIBITOR | IC50 | 5.33 | DRUG LABEL | ||||
| Cyclin-dependent kinase 1 | Kinase | INHIBITOR | IC50 | 5.53 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11130 | KEGG_DRUG |
| U6072DO9XG | UNII |
| 1977495-97-8 | SECONDARY_CAS_RN |
| C4524320 | UMLSCUI |
| CHEBI:231087 | CHEBI |
| CHEMBL3894860 | ChEMBL_ID |
| 68029831 | PUBCHEM_CID |
| DB15442 | DRUGBANK_ID |
| CHEMBL4650272 | ChEMBL_ID |
| 10565 | INN_ID |
| C000708352 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9626 | IUPHAR_LIGAND_ID |
| 1149152001 | SNOMEDCT_US |
| 1149273007 | SNOMEDCT_US |
| 1149274001 | SNOMEDCT_US |
| 4040108 | VANDF |
| 343885 | MMSL |
| 39327 | MMSL |
| d09715 | MMSL |
| 018637 | NDDF |
| 018638 | NDDF |
| 2479690 | RXNORM |
| U6072DO9XG | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| COSELA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73462-101 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 300 mg | INTRAVENOUS | NDA | 26 sections |
| COSELA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73594-0101 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 300 mg | INTRAVENOUS | NDA | 28 sections |